调节性B细胞与1型糖尿病  

Regulatory B cells and type 1 diabetes

作　　者：王悦舒[1] 张梅[1] Wang Yueshu Zhang Mei.(Department of Endocrinology, The First Affiliated Hospital of Nattjing Medical University, Nanjing 210029, China)

机构地区：[1]南京医科大学第一附属医院内分泌科,210029

出　　处：《国际内分泌代谢杂志》2017年第3期195-198,共4页International Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金资助项目（81070622,81370939）

摘　　要：1型糖尿病主要是由T细胞介导的针对胰岛β细胞的自身免疫性疾病,然而B细胞在1型糖尿病发生、发展中也发挥重要作用,B细胞去除可用于治疗1型糖尿病.调节性B细胞是近来研究发现的一群具有免疫负向调控作用的B细胞亚群.在1型糖尿病中存在调节性B细胞数量和功能的异常.探索调节性B细胞在1型糖尿病发病机制中所起的作用将提供更多的理论依据,为1型糖尿病免疫治疗提供新靶点和新思路.Type 1 diabetes mellitus （T1 DM） is an autoimmune disorder characterized by the T cell-mediated destruction of islet β cells.However,B cells also play critical roles in the occurrence and development of T1DM.B cells depletion could be used in the treatment of T1DM.To date,regulatory B cells （Bregs）,as immunosuppressive B cells,have been shown to play pivotal roles in the control of autoimmunity and pathological immune responses.Bregs are numerically and functionally impaired in T1 DM.Investigation of Bregs in the pathogenesis of T1DM will further provide the theoretical evidences and explore new targets and new ideas for the treatment of T1DM.

关 键 词：调节性B细胞 1型糖尿病 自身免疫性疾病 

分 类 号：R587.1[医药卫生—内分泌]